Scarica l'app Stockscreener
102.34
0.04%
0.04
Dopo l'orario di chiusura:
102.20
-0.14
-0.14%
Precedente Chiudi:
$102.30
Aprire:
$102.32
Volume 24 ore:
2.47M
Relative Volume:
0.47
Capitalizzazione di mercato:
$19.44B
Reddito:
$3.08B
Utile/perdita netta:
$-986.58M
Rapporto P/E:
-19.25
EPS:
-5.3172
Flusso di cassa netto:
$292.08M
1 W Prestazione:
+0.08%
1M Prestazione:
+0.43%
6M Prestazione:
+118.68%
1 anno Prestazione:
+82.65%
Intervallo 1D:
$102.31
$102.56
Intervallo di 1 settimana:
$102.11
$102.59
Portata 52W:
$38.81
$102.66
Exact Sciences Corp Stock (EXAS) Company Profile
Nome
Exact Sciences Corp
Settore
Industria
Telefono
608-284-5700
Indirizzo
5505 ENDEAVOR LANE, MADISON, WI
Confronta EXAS con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
EXAS
Exact Sciences Corp
|
102.34 | 19.43B | 3.08B | -986.58M | 292.08M | -5.3172 |
|
TMO
Thermo Fisher Scientific Inc
|
578.61 | 222.48B | 44.56B | 6.73B | 6.29B | 17.74 |
|
DHR
Danaher Corp
|
218.89 | 155.25B | 24.57B | 3.60B | 5.25B | 5.0475 |
|
IDXX
Idexx Laboratories Inc
|
670.46 | 54.04B | 4.17B | 1.03B | 940.22M | 12.61 |
|
IQV
Iqvia Holdings Inc
|
230.15 | 40.13B | 15.90B | 1.28B | 2.21B | 7.2842 |
|
A
Agilent Technologies Inc
|
133.85 | 37.78B | 6.95B | 1.30B | 1.15B | 4.5696 |
Exact Sciences Corp Stock (EXAS) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2026-01-20 | Downgrade | Mizuho | Outperform → Neutral |
| 2026-01-05 | Downgrade | Evercore ISI | Outperform → In-line |
| 2025-04-10 | Iniziato | Mizuho | Outperform |
| 2025-03-13 | Iniziato | RBC Capital Mkts | Sector Perform |
| 2025-01-23 | Iniziato | Barclays | Overweight |
| 2024-08-28 | Iniziato | Wells Fargo | Overweight |
| 2024-06-27 | Iniziato | Scotiabank | Sector Outperform |
| 2024-06-03 | Ripresa | Jefferies | Buy |
| 2024-01-02 | Aggiornamento | The Benchmark Company | Hold → Buy |
| 2023-12-14 | Iniziato | Guggenheim | Buy |
| 2023-12-13 | Iniziato | Wolfe Research | Outperform |
| 2023-10-10 | Aggiornamento | Piper Sandler | Neutral → Overweight |
| 2023-09-28 | Iniziato | Bernstein | Outperform |
| 2023-08-02 | Downgrade | The Benchmark Company | Buy → Hold |
| 2023-05-10 | Aggiornamento | Craig Hallum | Hold → Buy |
| 2023-05-05 | Iniziato | UBS | Neutral |
| 2023-03-09 | Aggiornamento | Citigroup | Neutral → Buy |
| 2023-02-10 | Downgrade | Credit Suisse | Outperform → Neutral |
| 2023-01-18 | Downgrade | Raymond James | Outperform → Mkt Perform |
| 2022-10-19 | Downgrade | Craig Hallum | Buy → Hold |
| 2022-08-25 | Iniziato | Credit Suisse | Outperform |
| 2022-06-03 | Iniziato | Piper Sandler | Neutral |
| 2021-11-03 | Downgrade | Raymond James | Strong Buy → Outperform |
| 2021-07-29 | Reiterato | BTIG Research | Buy |
| 2021-07-29 | Reiterato | Canaccord Genuity | Buy |
| 2021-07-29 | Reiterato | Oppenheimer | Outperform |
| 2021-07-29 | Reiterato | Stifel | Buy |
| 2021-06-15 | Iniziato | Raymond James | Strong Buy |
| 2021-06-03 | Iniziato | Goldman | Buy |
| 2021-05-25 | Iniziato | Wells Fargo | Equal Weight |
| 2021-01-28 | Iniziato | Truist | Buy |
| 2020-10-29 | Downgrade | UBS | Buy → Neutral |
| 2020-10-28 | Downgrade | Citigroup | Buy → Neutral |
| 2020-10-08 | Ripresa | BTIG Research | Buy |
| 2020-04-02 | Iniziato | Evercore ISI | Outperform |
| 2020-01-10 | Ripresa | BTIG Research | Buy |
| 2020-01-07 | Iniziato | Citigroup | Buy |
| 2019-12-13 | Iniziato | Dougherty & Company | Buy |
| 2019-11-15 | Iniziato | Stifel | Buy |
| 2019-10-17 | Reiterato | BofA/Merrill | Buy |
| 2019-10-01 | Ripresa | Craig Hallum | Buy |
| 2019-09-26 | Iniziato | Oppenheimer | Outperform |
| 2019-02-26 | Aggiornamento | Goldman | Neutral → Buy |
| 2018-10-09 | Iniziato | UBS | Buy |
| 2018-09-05 | Ripresa | The Benchmark Company | Hold |
| 2018-08-13 | Reiterato | Canaccord Genuity | Buy |
| 2018-04-03 | Aggiornamento | BTIG Research | Neutral → Buy |
| 2018-01-29 | Iniziato | Goldman | Neutral |
| 2018-01-08 | Reiterato | The Benchmark Company | Buy |
| 2017-11-13 | Downgrade | Robert W. Baird | Outperform → Neutral |
| 2017-11-01 | Downgrade | BTIG Research | Buy → Neutral |
Mostra tutto
Exact Sciences Corp Borsa (EXAS) Ultime notizie
Abbott Laboratories Resets Portfolio With Exact Sciences Cancer Diagnostics Deal - Yahoo Finance UK
Freedom Capital Markets upgrades Abbott Labs stock rating to Buy on Exact Sciences deal - Investing.com
Here Are Tuesday’s Top Wall Street Analyst Research Calls: Applied Materials, CDW, Exact Sciences, Harley-Davidson, Oshkosh, ServiceNow and More - AOL.com
Exact Sciences Corp. (EXAS) Rose Following the Acquisition Announcement - Insider Monkey
EFG Asset Management North America Corp. Purchases 12,900 Shares of Exact Sciences Corporation $EXAS - MarketBeat
3 Reasons to Buy This Dividend King After Its Steep Sell-Off - The Motley Fool
Baillie Gifford & Co. Lowers Holdings in Exact Sciences Corporation $EXAS - MarketBeat
A Look At Exact Sciences (EXAS) Valuation After Its Strong Recent Share Price Momentum - Yahoo Finance
Lobbying Update: $420,000 of EXACT SCIENCES lobbying was just disclosed - Quiver Quantitative
Halper Sadeh Investigates Potential Securities Violations by Penumbra, Exact Sciences, DigitalBridge, and Flushing Financial - Intellectia AI
Mizuho downgrades Exact Sciences (EXAS) - MSN
Short Squeeze: Is Village Farms International Inc stock a good pick for beginnersJuly 2025 Selloffs & AI Enhanced Trading Signals - baoquankhu1.vn
Assessing Exact Sciences: Insights From 16 Financial Analysts - Benzinga
Exact Sciences Corp.: How a Diagnostics Powerhouse Is Rewriting the Playbook on Early Cancer Detecti - AD HOC NEWS
Exact Sciences (EXAS) Downgraded by Mizuho, Price Target Raised to $105 | EXAS Stock News - GuruFocus
Here Are Tuesday’s Top Wall Street Analyst Research Calls: Chevron, Domino’s Pizza, Doximity, Exact Sciences, Intel, NetApp, StubHub, Toast, and More - AOL.com
Exact Sciences (EXAS) Rose Following the Acquisition Announcement by Abbott - Yahoo Finance
Here Are Tuesday’s Top Wall Street Analyst Research Calls: Chevron, Domino's Pizza, Doximity, Exact Sciences, Intel, NetApp, StubHub, Toast, and More - 24/7 Wall St.
Mizuho downgrades Exact Sciences stock to Neutral on Abbott acquisition - Investing.com
Mizuho downgrades Exact Sciences stock to Neutral on Abbott acquisition By Investing.com - Investing.com Nigeria
Exact Sciences’ MCED Test Study: A Potential Game-Changer in Early Cancer Detection - MSN
Exact Sciences Investor Alert: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Exact Sciences CorporationEXAS - marketscreener.com
Why Abbott Laboratories (ABT) Story Is Shifting With Exact Sciences Deal Talk And Legal Wins - Yahoo Finance
Robeco Institutional Asset Management B.V. Lowers Stake in Exact Sciences Corporation $EXAS - MarketBeat
Exact Sciences Corporation (EXAS) Stock Analysis: Strong Revenue Growth Amid High Valuation - DirectorsTalk Interviews
Exact Sciences (EXAS) Valuation Check After Strong Multi Month Share Price Momentum - Yahoo Finance
Is Exact Sciences (EXAS) Still Attractive After An 81% One Year Share Price Surge - Yahoo Finance
Is Exact Sciences Corporation stock a safe haven assetInsider Selling & Real-Time Volume Trigger Notifications - ulpravda.ru
Peregrine Capital Management LLC Grows Position in Exact Sciences Corporation $EXAS - MarketBeat
Will Exact Sciences Corporation stock benefit from sector rotationGold Moves & Low Drawdown Investment Strategies - ulpravda.ru
How Exact Sciences Corporation stock reacts to job market dataMarket Trend Report & Free AI Powered Buy and Sell Recommendations - ulpravda.ru
How Exact Sciences Corporation stock reacts to bond yieldsJuly 2025 Rallies & Risk Controlled Daily Plans - ulpravda.ru
Can Exact Sciences Corporation (EXK) stock retain market dominanceJuly 2025 Trends & Safe Capital Growth Trade Ideas - ulpravda.ru
Abbott’s $105 Bid Put Exact Sciences Back In Play - Finimize
Assessing Exact Sciences (EXAS) Valuation After A Strong Momentum-Driven Share Price Run - simplywall.st
EXAS Stock Rating Downgraded to 'In-Line' by Evercore ISI Group - GuruFocus
Exact Sciences Corporation (EXAS) Stock Analysis: Unveiling Growth Potential In Cancer Diagnostics - DirectorsTalk Interviews
Abbott bets on cancer screening with $23 billion Exact Sciences deal - MSN
Pharma News: Can Exact Sciences Corporation EXK stock retain market dominanceVolume Spike & Free Fast Entry Momentum Trade Alerts - moha.gov.vn
1 High-Flying Stock on Our Watchlist and 2 We Question - Finviz
Top 2 Health Care Stocks That May Crash In Q1 - Benzinga
Cwm LLC Purchases 28,975 Shares of Exact Sciences Corporation $EXAS - MarketBeat
Exact Sciences Stock Is Going Wild: Is This Cancer-Test Giant a Hidden Gem or Total Trap? - AD HOC NEWS
19,260 Shares in Exact Sciences Corporation $EXAS Purchased by Strait & Sound Wealth Management LLC - MarketBeat
Exact Sciences Corp.: Turning DNA Into a Weapon Against Cancer - AD HOC NEWS
Smart Oncology: 5 Stocks Chasing the $317B Prize - The Globe and Mail
Alert from law firm on Exact Sciences-Abbott deal withdrawn - marketscreener.com
Exact Sciences Shareholders Unhappy With $105 Per Share Sale to Abbott Should Contact Julie ... - Bluefield Daily Telegraph
Should You Continue to Hold EXAS Stock in Your Portfolio Now? - WV News
Exact Sciences Corp.: How a Diagnostics Powerhouse Is Rewriting the Cancer Playbook - AD HOC NEWS
Exact Sciences Corp. Stock Tests Investor Patience as Diagnostics Story Enters a New Act - AD HOC NEWS
Exact Sciences Corp Azioni (EXAS) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
1.19%
0.63%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):